Reproxalap Ophthalmic Solution (0.25%)
ADX-102-DED-021
Phase 3 small_molecule completed
Quick answer
Reproxalap Ophthalmic Solution (0.25%) for Dry Eye Disease is a Phase 3 program (small_molecule) at Aldeyra Therapeutics with 4 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Dry Eye Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed